Cutting edge issues in development: using markets for development? The potential of advanced market communities by Wani, Shahrukh
Cutting edge issues in development: using markets for development? 
The potential of advanced market communities
LSE Research Online URL for this paper: http://eprints.lse.ac.uk/102434/
Version: Published Version
Online resource:
Wani, Shahrukh (2018) Cutting edge issues in development: using markets for 
development? The potential of advanced market communities. LSE Department 
of International Development Blog (30 Jan 2018). Blog Entry. 
lseresearchonline@lse.ac.uk
https://eprints.lse.ac.uk/ 
Reuse
Items deposited in LSE Research Online are protected by copyright, with all rights 
reserved unless indicated otherwise. They may be downloaded and/or printed for private 
study, or other acts as permitted by national copyright laws. The publisher or other rights 
holders may allow further reproduction and re-use of the full text version. This is 
indicated by the licence information on the LSE Research Online record for the item.
  
Using Markets for Development? The Potential of Advanced Market 
Commitments 
LSE Department of International Development Blog 
Shahrukh Wani 
Markets are good for a lot of things. They have an irrefutable ability to cater to our demands, how 
seemingly ridiculous our demands might be. Think about silly putty. If enough people want it, 
they will get it. But there is a catch. You must be able to afford it. You can desire as much silly 
putty you want but if you can’t afford it or there isn’t demand from enough people to bring the per 
unit cost down for you to afford it, the market won’t deliver. 
The same limitation of market translates to a bigger problem for development practitioners. This 
means that if there is a demand for an essential product such as a vaccine from the cash-
strapped developing countries, but there isn’t demand for the same product from wealthier 
potential customers in the developed countries. The market won’t deliver. 
This means that there is a deficit of incentives for the market to provide a product to people who 
can’t afford it. In the case of vaccine’s, the challenge seems to be startling. The development of 
vaccines could save millions of lives, but pharmaceutical companies don’t have the incentive to 
put their money in research of these vaccines when there is little economic return. 
In a recent guest lecture at the London School of Economics, economist Owen Barder asked 
students to guess how much does the world spend seeking a cure for malaria in comparison to 
the global spending to cure male baldness. 
The answer, which most of us guessed correctly, is about a tenth. 
The reason is simple, pharmaceutical companies can’t offset the cost of developing malaria 
vaccine to the consumers unlike whatever remedy it develops for male baldness. “So, these 
companies are already taking the risk for rich countries who can pay more, but not for poor 
states who may not,” Owen says. 
The solution? Manipulating the markets so the vaccines demanded by lower-income countries 
work in a similar manner that those demanded by richer countries. This intuition made the 
basses of a 2005 report by the Centre for Global Development, which Owen co-authored. 
“Barely 10% of global R&D is devoted to diseases that affect 90% of the world’s population,” the 
report notes. 
The report proposed that the global donors to make an “advance market commitment (or AMC)” 
to pay for a certain number of successful pneumococcal vaccines, in turn offsetting research and 
development costs which the pharmaceutical companies would bear. “If it (vaccine) doesn’t work, 
it doesn’t cost us (the donors) anything.” 
The idea is strikingly simple. Instead of spending the money on sponsoring research for the 
vaccine, donors enter into a legal agreement with pharmaceutical companies for purchasing a 
number of vaccine in advance at a price high enough to incentivize companies to invest in 
research, in turn subsidising developing countries to save lives. 
When Owen and his colleagues told donors about the idea, the response was similar “it is such a 
good idea that somebody might have already done it.” 
The concept was luring enough that within months the G7 Finance Ministers backed the proposal 
in a conference in London. In 2009, this led to five countries, along with the Gates Foundation, to 
commit to $1.5 billion for a vaccine for pneumococcal diseases which, in 2005, had 
caused approximately 1.6 million deaths, almost exclusively in developing countries. 
By 2010, GlaxoSmithKline and Pfizer had announced a development of a pneumococcal vaccine 
under the AMC program. According to estimates, this vaccine would have averted 
approximately 1.5 million deaths among children by 2020. 
Despite this success, the concept hasn’t been replicated for other diseases. Owen admits that it 
is difficult in binding donors for a long-term commitment to buy these vaccines years from now. 
Owen admits that negotiating a legally binding contract was critical in the case of pneumococcal 
vaccine. 
Another challenge which Owen notes is the “distant lack of enthusiasm from disease researchers 
from bringing the drug companies in.” Referring to researchers who rely on grants to explore 
vaccines for diseases prevalent in developing countries. 
“You come on television and say that you will spend 1.5 billion of the taxpayer’s money, but the 
leading expert on the disease disagrees with you publically.” 
AMC’s provides evidence that incentivizing the market can work for solving key development 
challenges. But like most good ideas, it needs a lot of leg work, and even more, vibrant 
intellectual discourse among development thinkers. 
Can markets work for development? AMCs show that they can. As long as we remember that it’s 
all about the incentives.
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